Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Last trade$3.98
Day change-$0.08 (-1.97%)
Day range$3.94 – $4.12
Volume967,812
Market cap$1.32B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.32B
Price / earnings
—
Price / book
3.71×
Price / sales
241.18×
EV / sales
172.72×
EV / EBITDA
-5.8×
Profitability
Earnings per share
-$0.48
Return on assets
-35.87%
Return on equity
-43.71%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.13×
Current ratio
18.56×
Quick ratio
18.56×
Cash ratio
18.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$141.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TSHA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$5.49M
$0
$1.99M
$2.3M
$2.02M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$5.49M
$0
$1.99M
$2.3M
$2.02M
Selling, general and administrative
$13.11M
$12.15M
$9.68M
$8.83M
$8.28M
$8.6M
$8.16M
$6.63M
Research and development
$28.77M
$38.64M
$33.81M
$24.95M
$25.75M
$20.14M
$15.57M
$15.33M
Total operating expenses
$41.87M
$47.35M
$43.49M
$33.79M
$34.02M
$28.74M
$23.72M
$21.95M
Operating income
-$41.87M
-$47.35M
-$43.49M
-$28.3M
-$34.02M
-$26.75M
-$21.42M
-$19.93M
Interest expense
-$4K
-$6K
-$9K
-$12K
-$15K
-$17K
-$19K
-$22K
Income before taxes
-$39.13M
-$46.64M
-$42.41M
-$27.85M
-$32.73M
-$26.88M
-$21.53M
-$18.79M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$39.13M
-$46.64M
-$42.41M
-$27.85M
-$32.73M
-$26.88M
-$21.53M
-$18.79M
Net income attributable to common shareholders
-$39.13M
-$46.64M
-$42.41M
-$27.85M
-$32.73M
-$26.88M
-$21.53M
-$18.79M
EBITDA
-$41.62M
-$50.49M
-$43.19M
-$28M
-$33.74M
-$26.48M
-$21.14M
-$19.63M
Basic earnings per share
-$0.10
-$0.13
-$0.12
-$0.08
-$0.09
-$0.09
-$0.08
-$0.07
Diluted earnings per share
-$0.10
-$0.13
-$0.12
-$0.08
-$0.09
-$0.09
-$0.08
-$0.07
Recent news
Company coverage with links to the original publishers.
Taysha Gene Therapies granted five new employees 314,000 RSUs and options to purchase 92,400 shares as inducement for employment. The RSUs vest over four years, while stock options have a $5.70 exercise price and 10-year term with four-year vesting schedule.
Taysha Gene Therapies priced an underwritten public offering of 32.5 million shares at $6.00 per share and pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The offering is expected to close on June 26, 2026. The company is a clinical-stage biotech focused on AAV-based gene therapies for CNS diseases, with its lead program TSHA-102 in development for Rett syndrome.
Taysha Gene Therapies announced it will report Q1 2026 financial results and host a conference call on May 6, 2026. The clinical-stage biotech company is advancing AAV-based gene therapies for severe CNS monogenic diseases, with its lead program TSHA-102 in development for Rett syndrome.
Taysha Gene Therapies announced that on April 1, 2026, its Compensation Committee granted four new employees a total of 300,000 restricted stock units and options to purchase 92,400 shares at an exercise price of $4.31. The grants were made under the company's 2023 Inducement Plan as part of their employment agreements.
Taysha Gene Therapies reported full-year 2025 net loss of $109.0 million and announced significant progress in its lead program TSHA-102 for Rett syndrome treatment. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance for the ASPIRE trial in younger patients (ages 2-4). TSHA-102 maintained a favorable safety profile with no treatment-related serious adverse events. The company expects to complete dosing in both trials by Q2 2026 and has secured FDA alignment on manufacturing and regulatory strategy for its planned BLA submission. Cash position stands at $319.8 million, sufficient to fund operations into 2028.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.